Dactus 3 MG

105910019400503

Dactus 3 MG

8.50৳ 

Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)

Description

Generic

Glimepiride

 

Indications

Glimepiride is indicated in following conditions-

  • Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
  • Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.
  • Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent.
  • Combined use of Glimepiride and insulin may increase the potential for hypoglycaemia.

 

Pharmacology

Glimepiride may be a sulfonylurea antidiabetic operator which diminishes blood glucose concentration. The essential instrument of activity of Glimepiride shows up to be subordinate on invigorating the discharge of affront from working pancreatic beta cells. Glimepiride acts in concert with glucose by progressing the affectability of beta cells to physiological glucose boostcoming about in affront emission. In expansion, extrapancreatic impacts like decrease of basal hepatic glucose generationexpanded fringe tissue affectability to affront and glucose take-up may too play part within the action of Glimepiride. In non-fasting diabetic patients, the hypoglycaemic activity of a single measurements of Glimepiride continues for 24 hours.

 

Dosage & Administration

In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. The initial and the maintenance doses are set based on the results of regular check of glucose in blood and urine. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy.

Initial dose and dose titration: the usual initial dose is 1 mg once daily, if necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e., at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg -> 2 mg -> 3 mg -> 4 mg -> 6 mg.

Dose in patients with well controlled diabetes: the usual dose range in patients with well controlled diabetes is 1 to 4 mg daily.

Distribution of doses: Timing and distribution of doses are decided by the physician, in consideration of the patient’s current life-style. Normally, a single daily dose is sufficient. This should be taken immediately before a substantial breakfast or if none is taken immediately before the first main meal. It is very important not to skip meals after taking the drug.

Secondary dosage adjustment: As control of diabetes improves, sensitivity to insuiin increases; therefore, Glimepiride requirement may fall as treatment proceeds. To avoid hypoglycaemia, timely dose reduction or cessation of Glimepiride therapy must be considered. A dose adjustment must also be considered whenever the patient’s weight or life-styie changes, or other factors arise which cause an increased susceptibility to hypo or hyperglycaemia.

Changeover from other oral antidiabetics to Glimepiride: There is no exact dosage relationship between Glimepiride and other oral blood sugar lowering agents. When substituting Glimepiride for other such agents, the initial daily dose is 1 mg; this applies even in changeover from maximum dose of other oral blood sugar lowering agents. Any dose increase should be in accordance with guideline given above in ‘initial dose and dose titration’. Consideration must be given to the potency and duration of action of the previous blood sugar lowering agent. It may be necessary to interrupt treatment to avoid additive effects which would increase the risk of hypoglycaemia.

 

Interaction

Based on involvement with Glimepiride and known intelligent for other sulfonylureas, the taking after intuitive must be considered.

In expansion to affront and other verbal antidiabetic specialists, drugs which may potentiate the hypoglycaemic activity of Glimepiride incorporate: Expert inhibitors, aminosalicylic corrosive, anabolic steroids and male sex hormones, azapropazone, chloramphenicol, ciofibrate, coumarin subsidiaries, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluconazole, fluoxetine, guanethidine, ifosfamide, MAO-inhibitors, miconazole, oxpentifylline (tall dosage parenteral), oxyphenbutazone, para-aminosalicylic corrosive, phenylbutazone, probenecid, quinolones, salicylates, sulphinpyrazone, sulfonamide anti-microbials, tetracyclines, tritoqualine, trofosfamide.

Drugs which may attenuate the hypoglycaemic action of Glimepiride include:

  • Acetazoiamide, barbiturates, calcium channel blockers, corticosteroids, diazoxide, diuretics, glucagon, isoniazid, laxatives, nicotinic acid (high doses), oestrogens, phenothiazines, phenytoin, progestagens, rifampicin, sympathomimetic agents, thyroid hormones.
  • H2 receptor antagonists, beta-blockers, clonidine and reserpine may lead to either potentiation or weakening of the blood-glucose-lowering effect.
  • Concomitant treatment with a beta-receptor blocker, clonidine, guanethidine or reserpine may mask the warning symptoms of a hypoglycaemic attack.
  • Acute and chronic aicohol intake may either potentiate or attenuate the activity of Glimepiride in an unpredictable fashion.

 

Contraindications

Tendinitis and tendon rupture are possible side effects of moxifloxacin. If a tendon becomes inflamed or painful, it should be stopped. It should not be used in individuals who have a known prolongation of the QT interval, hypokalemia that has not been addressed, or who are taking Class IA or Class III antiarrhythmics.

 

Side Effects

Hypoglycemia, transient vision impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, and a drop in blood pressure are all symptoms of hypoglycemia.

 

Pregnancy & Lactation

Glimepiride should not be used during pregnancy; instead, insulin should be used. Patients who are considering a pregnancy should tell their doctor and switch to insulin. The child may be harmed if Glimepiride is consumed while breast-feeding. As a result, women who are breastfeeding should avoid using Glimepiride. Either a switchover or a full stoppage of nursing is required.

 

Precautions & Warnings

The risk of hypoglycemia may be higher in the first few weeks of treatment, necessitating cautious monitoring. If such a danger exists, the dosage of Glimepiride may need to be adjusted. Hypoglycemia may nearly always be corrected with immediate carbohydrate ingestion (glucose or sugar).

 

Therapeutic Class

Sulfonylureas

 

Storage Conditions

 

Do not store above 30°C. Keep away from light and out of the reach of children.

 

Pharmaceuticals name

ACME Laboratories Ltd.